Term
|
Definition
S Phase
Folate-> Tetrahyrofolic Acid
Renal Toxicity
Immunosupressive |
|
|
Term
|
Definition
|
|
Term
|
Definition
Purine precursor -> IMP
IMP -> Ribonucleotides |
|
|
Term
|
Definition
S Phase
Ribonucleases -> Deoxyribonucleases
Nucleotides _ DNA
Cytosine -> Nucleotides |
|
|
Term
|
Definition
Purine precursor -> IMP
IMP -> Ribonucleotides |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Antibiotics
Pulmonary Toxcity |
|
|
Term
|
Definition
|
|
Term
| platinum complexes (Cisplatin) |
|
Definition
|
|
Term
|
Definition
| leukemia and pulmonary toxicity |
|
|
Term
|
Definition
|
|
Term
|
Definition
| targets ribonucleotide reductase and prevents the conversation of nucleotide to deoynucleotides, and DNA synthesis |
|
|
Term
|
Definition
targets guanine residues and causes intra-strand DNA crosslinks
G0 Phase |
|
|
Term
|
Definition
| targets topoisomerase II and stabilizes double-stranded DNA beaks |
|
|
Term
|
Definition
binds DNA and chelates iron to cause free radical-induced DNA strand breaks.
G2 Phase |
|
|
Term
| Cisplatin and bleomycin damage DNA, while etoposide (VP-16) inhibits DNA repair. (T/F) |
|
Definition
|
|
Term
How does signaling through the EGFR promote cell growth
and survival? |
|
Definition
| Intracellular signals promote activation of genes involved cell proliferation. |
|
|
Term
| Elotinib (TKI) targets EGF to block cancer cell growth T/F |
|
Definition
F
Tyrosine Kinase Inhibitors can only bind to tyrosine kinase receptor
Mab can bind both receptor and ligand |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
Cisplatin
iomustine
procarbazine |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
vinblastine
Vincristine
paclitaxel |
|
|
Term
|
Definition
erlotinib
imatinib
sorafenib
sunitinib
tretinoin
herceptin |
|
|
Term
|
Definition
Bleomycin
hydroxyurea
predisone |
|
|
Term
|
Definition
| Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, binds to the extracellular domain of the HER2 protein, which is overexpressed in 25 to 30% of primary breast cancers. By binding to the HER2 protein, trastuzumab inhibits the growth of tumor cells and mediates antibody-dependent cellular cytotoxicity (ADCC) in cancer cells that overexpress the HER2 protein |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| Farnesyltransferase inhibitors |
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
| 3 advantages of combination therapy |
|
Definition
1. Suppression of drug resistance - less chance of a cell developing resistance to 2 drugs than to 1 drug.
2. Increased cancer cell kill - administration of drugs with different mechanisms of action.
3. Reduced injury to normal cells - by using a combination of drugs that do not have overlapping toxicities, we can achieve a greater anticancer effect than we could by using any one agent alone. |
|
|
Term
|
Definition
| Adriamycin, bleomycin, vinblastine, dacarbazine |
|
|
Term
|
Definition
| mustard, vincristine (Oncovin), procarbazine, prednisone |
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
Term
|
Definition
|
|
